Uncover the long-term efficacy and safety profile of Ebglyss (Lebrikizumab) from the ADjoin clinical trial, demonstrating 2 years of sustained relief for patients with moderate-to-severe Atopic Dermatitis (AD). See how Ebglyss continues to Last Long with Monthly Maintenance Dosing, with a robust safety profile through extended treatment1
